Pipeline

# A focused, late-stage pipeline

Our lead therapy — a biomarker-driven, oral WEE1 inhibitor — anchors a disciplined development program designed to reach patients efficiently across multiple difficult-to-treat indications.

Clinical program details → Our science

Overview

## Program status at a glance

Zentia clinical pipeline overview
Program | Indication | Mechanism | Phase | Status
--- | --- | --- | --- | ---
Zent-001 (oral WEE1 inhibitor) | Cyclin E1-positive platinum-resistant ovarian cancer | WEE1 kinase inhibition | Phase 3 | Enrolling · ASPENOVA
Zent-001 | Uterine serous carcinoma | WEE1 kinase inhibition | Phase 2 | Registration-intent
Zent-002 (next-gen) | Additional WEE1-driven tumors | Next-generation WEE1 inhibitor | Phase 1 | Exploring
Combination strategy | Rational combinations | WEE1 inhibitor + standard agents | Preclinical | In development

0 Late-stage clinical programs
0 Clinical trial sites worldwide
0 Patients dosed across programs
0 Years of WEE1 research
Lead asset Zent-001 An oral, once-daily WEE1 inhibitor in registration-intent development.

Lead program

## Zent-001 leads the WEE1 field

Zent-001 is a first-in-class, oral, once-daily WEE1 inhibitor. By blocking the checkpoint cancer cells rely on, it drives tumor cells toward cell death while being designed for convenient at-home administration.

Developed alongside a companion diagnostic, Zent-001 is being evaluated in biomarker-defined populations where a non-chemotherapy option could change the standard of care.

- Registration-intent Phase 3 in ovarian cancer
- Companion diagnostic developed in parallel
- Oral, once-daily dosing — no infusion visits

Clinical programs → Speak with our team

Investors

## See the full story behind the pipeline

Our investor presentation walks through the science, the data and the path to registration.

View investor presentation → Latest news